Wednesday, August 12, 2020 8:52:51 PM
$ADMS | #AdamasPharmaceuticals Upside Targets
Adamas Pharmaceuticals , Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Official InvestorsHub (IHUB) Profile for #TFMG | #theFinancialMarketingGroup:
#BullishCharts - https://investorshub.advfn.com/BullishChartscom-38003/
#TopMarketGainers - https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
